IDH2 and astrocytoma (excluding glioblastoma): Based on the preclinical finding, CB-839, combined with radiation and temozolomide, is being utilized in phase 1 clinical trial of IDH-mutant astrocytoma (Table 2; ClinicalTrials.gov NCT03528642).